Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMF in Relapsed/Refractory CLL/SLL
NCT02784834Phase 1Terminated
- Start
- Jun 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dimethyl fumarate in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (3 cohorts). Primary endpoint: Incidence of Dose Limiting Toxicity at 2 months. Started Jun 2016; status: terminated.
02
Drugs
dimethyl fumarate
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02784834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784834.